NTM-006
Acute and chronic pain
Phase 2Active
Key Facts
About Neumentum
Neumentum is a private, pre-revenue biotech focused on transforming pain treatment through a pipeline of non-opioid analgesics. Its lead assets include NTM-001, a late-stage, novel formulation of ketorolac for continuous infusion, and NTM-006, a novel oral compound with a new mechanism of action. The company is targeting a massive market driven by the opioid crisis and the critical need for effective, safer pain management alternatives, led by an experienced team with deep expertise in pain drug development and commercialization.
View full company profileOther Acute and chronic pain Drugs
| Drug | Company | Phase |
|---|---|---|
| KNX101 | Kinoxis Therapeutics | Preclinical/IND‑enabling |
| MAX-001 | Maxona Pharmaceuticals | Phase 2 |
| Pain Therapy Portfolio | Molteni Farmaceutici | Approved |